Test ID: HCMGG Hypertrophic Cardiomyopathy Gene Panel, Varies
Ordering Guidance
This test is intended for genetic screening for and diagnosis of hypertrophic cardiomyopathy.
For comprehensive cardiomyopathy genetic testing, order CCMGG / Comprehensive Cardiomyopathy Gene Panel, Varies.
Customization of this panel and single gene analysis for any gene present on this panel are available. For more information see CGPH/ Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.
Targeted testing for familial variants (also called site-specific or known mutations testing) is available for the genes on this panel. See FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.
Shipping Instructions
Specimen preferred to arrive within 96 hours of collection.
Necessary Information
Prior Authorization is available, but not required, for this test. If proceeding with the prior authorization process, submit the required form with the specimen.
Specimen Required
Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.
Specimen Type: Whole blood
Container/Tube:
Preferred: Lavender top (EDTA) or yellow top (ACD)
Acceptable: Any anticoagulant
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
Specimen Stability Information: Ambient (preferred)/Refrigerated
Forms
1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file.
The following documents are available:
-Informed Consent for Genetic Testing (T576)
-Informed Consent for Genetic Testing (Spanish) (T826)
2. Hereditary Cardiomyopathies and Arrhythmias Patient Information
3. Hypertrophic Cardiomyopathy Panel (HCMGG) Prior Authorization Ordering Instructions
4. If not ordering electronically, complete, print, and send a Cardiovascular Test Request Form (T724) with the specimen.
Useful For
Providing a genetic evaluation for patients with a personal or family history suggestive of a hereditary form of hypertrophic cardiomyopathy
Establishing a diagnosis of a hereditary form of hypertrophic cardiomyopathy
Genetics Test Information
This test utilizes next-generation sequencing to detect single nucleotide and copy number variants in 48 genes associated with hereditary forms of hypertrophic cardiomyopathy: ACAD9, ACADVL, ACTC1, ACTN2, AGL, ALPK3, BRAF, CPT2, CSRP3, ELAC2, FHL1, FLNC, GAA, GLA, HRAS, JPH2, KRAS, LAMP2, LZTR1, MAP2K1, MAP2K2, MRAS, MTO1, MYBPC3, MYH7, MYL2, MYL3, NEXN, NRAS, PLN, PPA2, PRKAG2, PTPN11, RAF1, RIT1, SHOC2, SLC22A5, SOS1, SOS2, TCAP, TMEM70, TNNC1, TNNI3, TNNT2, TPM1, TRIM63, TTR, and VCL. See Targeted Genes and Methodology Details for Hypertrophic Cardiomyopathy Gene Panel and Method Description for additional details.
Â
Identification of a disease-causing variant may assist with diagnosis, prognosis, clinical management, familial screening, and genetic counseling for hereditary forms of hypertrophic cardiomyopathy.
Prior Authorization is available for this assay.
Method Name
Sequence Capture and Targeted Next-Generation Sequencing followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing
Reporting Name
Hypertrophic Cardiomyopathy PanelSpecimen Type
VariesSpecimen Minimum Volume
1 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Varies |
Clinical Information
Cardiomyopathies are a group of disorders characterized by disease of the heart muscle. Cardiomyopathy can be caused by either inherited, genetic factors or nongenetic (acquired) causes, such as infection or trauma.(1) When the presence or severity of the cardiomyopathy observed in a patient cannot be explained by acquired causes, genetic testing for the inherited forms of cardiomyopathy may be considered.
The hereditary form of hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy in the absence of other cardiac or systemic causes that may cause hypertrophy of the heart muscle, such as longstanding, uncontrolled hypertension or aortic stenosis. The incidence of HCM in the general population is approximately 1:200 to1:500, and it is estimated that 30% to 60% of cases can be attributed to a genetic etiology.(1) Hereditary forms of HCM are most often caused by genes encoding proteins of the cardiac sarcomere, the functional contractile unit of the heart muscle.
The clinical presentation of HCM can be variable, even within the same family. HCM can be apparently asymptomatic in some individuals but can cause sudden, life-threatening arrhythmias, increasing the risk of sudden cardiac death. Additionally, HCM may also be a feature of an underlying systemic condition such as Noonan syndrome, a mitochondrial disorder, or a metabolic storage disorder.(2)
Hereditary forms of HCM can follow autosomal dominant, autosomal recessive, and X-linked patterns of inheritance. Mitochondrial inheritance is also possible, however, genes associated with mitochondrial inheritance of HCM are not assessed on this panel.
Reference Values
An interpretive report will be provided.
Interpretation
All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations.(3) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.
Clinical Reference
1. Ommen SR, Mital S, Burke MA, et al: 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: Executive Summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2020;142(25):e533-e557. doi: 10.1161/CIR.0000000000000938
2. Authors/Task Force members, Elliott PM, Anastasakis A, et al: 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014 Oct;35(39):2733-2779. doi: 10.1093/eurheartj/ehu284
3. Richards S, Aziz N, Bale S, et al: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405-424. doi: 10.1038/gim.2015.30
Day(s) Performed
Varies
Report Available
14 to 28 daysTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81439
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
HCMGG | Hypertrophic Cardiomyopathy Panel | 81860-9 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
617282 | Test Description | 62364-5 |
617283 | Specimen | 31208-2 |
617284 | Source | 31208-2 |
617285 | Result Summary | 50397-9 |
617286 | Result | 82939-0 |
617287 | Interpretation | 69047-9 |
617288 | Additional Results | 82939-0 |
617289 | Resources | 99622-3 |
617290 | Additional Information | 48767-8 |
617291 | Method | 85069-3 |
617292 | Genes Analyzed | 48018-6 |
617293 | Disclaimer | 62364-5 |
617294 | Released By | 18771-6 |
mcl-moltechtestmenu; mcl-cardiology